Editorial commentary: Polymyxin-resistant Acinetobacter baumannii: urgent action needed.
作者信息
Pogue Jason M, Cohen David A, Marchaim Dror
机构信息
Department of Pharmacy Services, Sinai-Grace Hospital, Detroit Medical Center, Wayne State University School of Medicine, Michigan.
Unit of Infectious Diseases, Assaf Harofeh Medical Center, Zerifin.
出版信息
Clin Infect Dis. 2015 May 1;60(9):1304-7. doi: 10.1093/cid/civ044. Epub 2015 Jan 28.
Abstract
摘要
相似文献
1
Editorial commentary: Polymyxin-resistant Acinetobacter baumannii: urgent action needed.
Clin Infect Dis. 2015 May 1;60(9):1304-7. doi: 10.1093/cid/civ044. Epub 2015 Jan 28.
2
Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.
Clin Infect Dis. 2015 May 1;60(9):1295-303. doi: 10.1093/cid/civ048. Epub 2015 Jan 28.
3
Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.
J Antimicrob Chemother. 2017 May 1;72(5):1415-1420. doi: 10.1093/jac/dkx002.
4
Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii.
J Med Assoc Thai. 2010 Feb;93(2):161-71.
5
Evaluation of the Colistin-Carbapenem Combination in Clinical Isolates of Using the Checkerboard, Etest, and Time-Kill Curve Techniques.
Front Cell Infect Microbiol. 2017 May 24;7:209. doi: 10.3389/fcimb.2017.00209. eCollection 2017.
6
In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
Ann Lab Med. 2016 Mar;36(2):124-30. doi: 10.3343/alm.2016.36.2.124.
7
In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
J Int Med Res. 2013 Dec;41(6):1830-7. doi: 10.1177/0300060513496172.
8
Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: mechanisms of resistance, molecular identification and epidemiological data.
BMC Infect Dis. 2015 Dec 9;15:559. doi: 10.1186/s12879-015-1297-x.
9
In Vitro Bactericidal Activity of Trimethoprim-Sulfamethoxazole Alone and in Combination with Colistin against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates.
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6903-6906. doi: 10.1128/AAC.01082-16. Print 2016 Nov.
10
The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit.
BMC Infect Dis. 2015 Sep 30;15:393. doi: 10.1186/s12879-015-1133-3.
引用本文的文献
1
Exploring Aspartate Transcarbamoylase: A Promising Broad-Spectrum Target for Drug Development.
Chembiochem. 2025 Apr 1;26(7):e202401009. doi: 10.1002/cbic.202401009. Epub 2025 Mar 27.
2
Colistin resistance in carbapenem non-susceptible Acinetobacter baumanii in a tertiary care hospital in India: clinical characteristics, antibiotic susceptibility and molecular characterization.
Mol Biol Rep. 2024 Feb 24;51(1):357. doi: 10.1007/s11033-023-08982-5.
3
Comparative metabolomics reveals key pathways associated with the synergistic activity of polymyxin B and rifampicin combination against multidrug-resistant Acinetobacter baumannii.
Biochem Pharmacol. 2021 Feb;184:114400. doi: 10.1016/j.bcp.2020.114400. Epub 2020 Dec 30.
4
A Diverse Panel of Clinical Acinetobacter baumannii for Research and Development.
Antimicrob Agents Chemother. 2020 Sep 21;64(10). doi: 10.1128/AAC.00840-20.
5
Colistin-Resistant Bacteremia: A Serious Threat for Critically Ill Patients.
Microorganisms. 2020 Feb 20;8(2):287. doi: 10.3390/microorganisms8020287.
6
Unlocking NuriPep 1653 From Common Pea Protein: A Potent Antimicrobial Peptide to Tackle a Pan-Drug Resistant .
Front Microbiol. 2019 Sep 18;10:2086. doi: 10.3389/fmicb.2019.02086. eCollection 2019.
7
[New antibiotics for severe infections due to multidrug-resistant pathogens : Definitive treatment and escalation].
Anaesthesist. 2019 Nov;68(11):785-800. doi: 10.1007/s00101-019-00646-z.
8
Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant Acinetobacter baumannii Clinical Isolates.
mBio. 2019 Jul 16;10(4):e01083-19. doi: 10.1128/mBio.01083-19.
9
spp. as nosocomial pathogens: Epidemiology and resistance features.
Saudi J Biol Sci. 2018 Mar;25(3):586-596. doi: 10.1016/j.sjbs.2016.02.009. Epub 2016 Feb 11.
10
spp. Infections in Malaysia: A Review of Antimicrobial Resistance Trends, Mechanisms and Epidemiology.
Front Microbiol. 2017 Dec 12;8:2479. doi: 10.3389/fmicb.2017.02479. eCollection 2017.
本文引用的文献
1
Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.
Clin Infect Dis. 2015 May 1;60(9):1295-303. doi: 10.1093/cid/civ048. Epub 2015 Jan 28.
2
A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections.
Clin Infect Dis. 2014 Dec 1;59 Suppl 6:S374-80. doi: 10.1093/cid/ciu613.
3
Acinetobacter sp. isolates from emergency departments in two hospitals of South Korea.
J Med Microbiol. 2014 Oct;63(Pt 10):1363-1368. doi: 10.1099/jmm.0.075325-0. Epub 2014 Jul 25.
4
Spread of a carbapenem- and colistin-resistant Acinetobacter baumannii ST2 clonal strain causing outbreaks in two Sicilian hospitals.
J Hosp Infect. 2014 Apr;86(4):260-6. doi: 10.1016/j.jhin.2014.02.001. Epub 2014 Feb 20.
5
Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women.
Antimicrob Agents Chemother. 2014;58(4):2113-8. doi: 10.1128/AAC.02036-13. Epub 2014 Jan 27.
6
New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.
Antimicrob Agents Chemother. 2014;58(4):1835-46. doi: 10.1128/AAC.00826-13. Epub 2013 Dec 30.
7
Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Drugs. 2014 Jan;74(1):31-51. doi: 10.1007/s40265-013-0168-2.
8
Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.
Antimicrob Agents Chemother. 2013 Nov;57(11):5548-58. doi: 10.1128/AAC.01288-13. Epub 2013 Aug 26.
9
Impaired virulence and fitness of a colistin-resistant clinical isolate of Acinetobacter baumannii in a rat model of pneumonia.
Antimicrob Agents Chemother. 2013 Oct;57(10):5120-1. doi: 10.1128/AAC.00700-13. Epub 2013 Jul 8.
10
Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness.
Antimicrob Agents Chemother. 2013 Sep;57(9):4587-9. doi: 10.1128/AAC.00543-13. Epub 2013 Jul 8.
Zotero 插件